Dealing with the complex drug-drug interactions: Towards mechanistic models

Biopharmaceutics and Drug Disposition

Volumn 36, Issue 2, 2015, Pages 71-92

  Varma, Manthena V ^a   Pang, K Sandy ^b   Isoherranen, Nina ^c   Zhao, Ping ^d  

^a PFIZER INC   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF WASHINGTON   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

CYP; drug drug interactions; metabolites; physiologically based pharmacokinetic model; transporters

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; DRUG METABOLIZING ENZYME; CARRIER PROTEIN;

AREA UNDER THE CURVE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DEVELOPMENT; DRUG DIFFUSION; DRUG DISPOSITION; DRUG INTERACTION; DRUG MECHANISM; DRUG METABOLISM; DRUG TRANSPORT; GENETIC POLYMORPHISM; HUMAN; INTRINSIC CLEARANCE; LIVER CLEARANCE; LIVER METABOLISM; LIVER MICROSOME; NONHUMAN; PHARMACOGENOMICS; REVIEW; BIOLOGICAL MODEL; DRUG EFFECTS; INTESTINE; LIVER; METABOLISM;

CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; INTESTINES; LIVER; MEMBRANE TRANSPORT PROTEINS; MODELS, BIOLOGICAL;

EID: 84924580597     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.1934     Document Type: Review

References (135)

1. Giacomini KM, Huang SM, Tweedie DJ, et al., Membrane transporters in drug development. Nat Rev Drug Discov 2010; 9: 215-236.
2. Lin JH, Lu AY,. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 1998; 35: 361-390.
3. Nebert DW, Russell DW,. Clinical importance of the cytochromes P450. Lancet 2002; 360: 1155-1162.
4. Yoshida K, Maeda K, Sugiyama Y,. Transporter-mediated drug-drug interactions involving OATP substrates: predictions based on in vitro inhibition studies. Clin Pharmacol Ther 2012; 91: 1053-1064.
5. Guengerich FP,. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999; 39: 1-17.
6. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, Sugiyama Y,. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 1998; 50: 387-412.
7. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, Tremaine LM,. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 2006; 316: 336-348.
8. Ito K, Hallifax D, Obach RS, Houston JB,. Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm. Drug Metab Dispos 2005; 33: 837-844.
9. Wienkers LC, Heath TG,. Predicting in vivo drug interactions from in vitro drug discovery data. Nature Rev Drug Discov 2005; 4: 825-833.
10. Di L, Feng B, Goosen TC, et al., A perspective on the prediction of drug pharmacokinetics and disposition in drug research and development. Drug Metab Dispos 2013; 41: 1975-1993.
11. Fahmi OA, Hurst S, Plowchalk D, et al., Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction. Drug Metab Dispos 2009; 37: 1658-1666.
12. Fahmi OA, Maurer TS, Kish M, Cardenas E, Boldt S, Nettleton D,. A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro. Drug Metab Dispos 2008; 36: 1698-1708.
13. Rostami-Hodjegan A, Tucker GT,. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 2007; 6: 140-148.
14. Sinha VK, Snoeys J, Osselaer NV, Peer AV, Mackie C, Heald D,. From preclinical to human-prediction of oral absorption and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in an industrial setting: a workflow by using case example. Biopharm Drug Dispos 2012; 33: 111-121.
15. Vieira ML, Kirby B, Ragueneau-Majlessi I, et al., Evaluation of various static in vitro-in vivo extrapolation models for risk assessment of the CYP3A inhibition potential of an investigational drug. Clin Pharmacol Ther 2014; 95: 189-198.
16. Barton HA, Lai Y, Goosen TC, et al., Model-based approaches to predict drug-drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond. Expert Opin Drug Metab Toxicol 2013; 9: 459-472.
17. Rowland M, Peck C, Tucker G,. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol 2011; 51: 45-73.
18. USFDA. Drug Interaction Studies-Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. Center for Drug Evaluation and Research (CDER) 2012.
19. Vieira M, Kim M, Apparaju S, et al., PBPK model describes the effects of comedication and genetic polymorphism on systemic exposure of drugs that undergo multiple clearance pathways. Clin Pharmacol Ther 2014; 95: 550-557.
20. Fenner KS, Jones HM, Ullah M, et al., The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance. Xenobiotica 2012; 42: 28-45.
21. Kalliokoski A, Niemi M,. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 2009; 158: 693-705.
22. Shitara Y, Sugiyama Y,. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 2006; 112: 71-105.
23. Shitara Y, Horie T, Sugiyama Y,. Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci 2006; 27: 425-446.
24. Maeda K, Ikeda Y, Fujita T, et al., Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study. Clin Pharmacol Ther 2011; 90: 575-581.
25. Prueksaritanont T, Chu X, Evers R, et al., Pitavastatin is a more sensitive and selective OATP1B clinical probe than rosuvastatin. Br J Clin Pharmacol 2014; 78: 587-598.
26. Group SC, Link E, Parish S, et al., SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med 2008; 359: 789-799.
27. Ieiri I, Higuchi S, Sugiyama Y,. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin Drug Metab Toxicol 2009; 5: 703-729.
28. Niemi M, Neuvonen PJ, Hofmann U, et al., Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype 17. Pharmacogenet Genomics 2005; 15: 303-309.
29. Nishizato Y, Ieiri I, Suzuki H, et al., Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 2003; 73: 554-565.
30. Shitara Y, Maeda K, Ikejiri K, Yoshida K, Horie T, Sugiyama Y,. Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. Biopharm Drug Dispos 2013; 34: 45-78.
31. Pang KS, Maeng HJ, Fan J,. Interplay of transporters and enzymes in drug and metabolite processing. Mol Pharm 2009; 6: 1734-1755.
32. Yoshida K, Maeda K, Sugiyama Y,. Hepatic and intestinal drug transporters: prediction of pharmacokinetic effects caused by drug-drug interactions and genetic polymorphisms. Annu Rev Pharmacol Toxicol 2013; 53: 581-612.
33. Liu L, Pang KS,. The roles of transporters and enzymes in hepatic drug processing. Drug Metab Dispos 2005; 33: 1-9.
34. Pang KS, Rowland M,. Hepatic clearance of drugs. I. Theoretical considerations of a 'well-stirred' model and a 'parallel tube' model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm 1977; 5: 625-653.
35. Roberts M, Rowland M,. Hepatic elimination-dispersion model. J Pharm Sci 1985; 74: 585-587.
36. Roberts MS, Rowland M,. A dispersion model of hepatic elimination: 2. Steady-state considerations-influence of hepatic blood flow, binding within blood, and hepatocellular enzyme activity. J Pharmacokinet Biopharm 1986; 14: 261-288.
37. Camenisch G, Umehara K,. Predicting human hepatic clearance from in vitro drug metabolism and transport data: a scientific and pharmaceutical perspective for assessing drug-drug interactions. Biopharm Drug Dispos 2012; 33: 179-194.
38. Varma MV, Lin J, Bi YA, et al., Quantitative prediction of repaglinide-rifampicin complex drug interactions using dynamic and static mechanistic models: delineating differential CYP3A4 induction and OATP1B1 inhibition potential of rifampicin. Drug Metab Dispos 2013; 41: 966-974.
39. Zamek-Gliszczynski MJ, Lee CA, Poirier A, et al., and International Transporter C. ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans. Clin Pharmacol Ther 2013; 94: 64-79.
40. De Buck SS, Sinha VK, Fenu LA, Nijsen MJ, Mackie CE, Gilissen RA,. Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs. Drug Metab Dispos 2007; 35: 1766-1780.
41. Jones HM, Gardner IB, Collard WT, et al., Simulation of human intravenous and oral pharmacokinetics of 21 diverse compounds using physiologically based pharmacokinetic modelling. Clin Pharmacokinet 2011; 50: 331-347.
42. Rowland M, Matin SB,. Kinetics of drug-drug interactions. J Pharmacokinet Pharmacodyn 1973; 1: 553-567.
43. Hu ZY,. Disposition pathway-dependent approach for predicting organic anion-transporting polypeptide-mediated drug-drug interactions. Clin Pharmacokinet 2013; 52: 433-441.
44. Watanabe T, Kusuhara H, Sugiyama Y,. Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humans. J Pharmacokinet Pharmacodyn 2010; 37: 575-590.
45. Jamei M, Marciniak S, Feng K, Barnett A, Tucker G, Rostami-Hodjegan A,. The Simcyp population-based ADME simulator. Expert Opin Drug Metab Toxicol 2009; 5: 211-223.
46. Varma MV, Lai Y, Feng B, Litchfield J, Goosen TC, Bergman A,. Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions. Pharm Res 2012; 29: 2860-2873.
47. Varma MV, Lai Y, Kimoto E, Goosen TC, El-Kattan AF, Kumar V,. Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide. Pharm Res 2013; 30: 1188-1199.
48. Kanamitsu S, Ito K, Sugiyama Y,. Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: use of maximum unbound concentration of inhibitor at the inlet to the liver. Pharm Res 2000; 17: 336-343.
49. Karlgren M, Ahlin G, Bergstrom CA, Svensson R, Palm J, Artursson P,. In vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions. Pharm Res 2012; 29: 411-426.
50. Karlgren M, Vildhede A, Norinder U, et al., Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem 2012; 55: 4740-4763.
51. Damle B, Varma MV, Wood N,. Pharmacokinetics of voriconazole administered concomitantly with fluconazole and population-based simulation for sequential use. Antimicrob Agents Chemother 2011; 55: 5172-5177.
52. Guest EJ, Rowland-Yeo K, Rostami-Hodjegan A, Tucker GT, Houston JB, Galetin A,. Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models. Br J Clin Pharmacol 2011; 71: 72-87.
53. Peters SA, Schroeder PE, Giri N, Dolgos H,. Evaluation of the use of static and dynamic models to predict drug-drug interaction and its associated variability: impact on drug discovery and early development. Drug Metab Dispos 2012; 40: 1495-1507.
54. Varma MV, Scialis R, Lin J, et al., Mechanism-based pharmacokinetic modeling to evaluate transporter-enzyme interplay in drug interactions and pharmacogenetics of glyburide. AAPS Journal 2014; 16: 736-748.
55. Jones HM, Barton HA, Lai Y, et al., Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data. Drug Metab Dispos 2012; 40: 1007-1017.
56. Li R, Barton HA, Yates PD, et al., A 'middle-out' approach to human pharmacokinetic predictions for OATP substrates using physiologically-based pharmacokinetic modeling. J Pharmacokinet Pharmacodyn 2014; 41: 197-209.
57. Jamei M, Bajot F, Neuhoff S, et al., A mechanistic framework for in vitro-in vivo extrapolation of liver membrane transporters: prediction of drug-drug interaction between rosuvastatin and cyclosporine. Clin Pharmacokinet 2014; 53: 73-87.
58. Varma MV, Scialis RJ, Lin J, et al., Mechanism-based pharmacokinetic modeling to evaluate transporter-enzyme interplay in drug interactions and pharmacogenetics of glyburide. AAPS J 2014; 16: 736-748.
59. Varma MV, Bi YA, Kimoto E, Lin J,. Quantitative prediction of transporter- and enzyme-mediated clinical drug-drug interactions of organic anion-transporting polypeptide 1B1 substrates using a mechanistic net-effect model. J Pharmacol Exp Ther 2014; 351: 214-223.
60. Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT,. CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide. Br J Clin Pharmacol 2003; 56: 305-314.
61. Kajosaari LI, Laitila J, Neuvonen PJ, Backman JT,. Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin. Basic Clin Pharmacol Toxicol 2005; 97: 249-256.
62. Sall C, Houston JB, Galetin A,. A comprehensive assessment of repaglinide metabolic pathways: impact of choice of in vitro system and relative enzyme contribution to in vitro clearance. Drug Metab Dispos 2012; 40: 1279-1289.
63. Kajosaari LI, Niemi M, Neuvonen M, Laitila J, Neuvonen PJ, Backman JT,. Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin Pharmacol Ther 2005; 78: 388-399.
64. Niemi M, Backman JT, Kajosaari LI, et al., Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther 2005; 77: 468-478.
65. Ogilvie BW, Zhang D, Li W, et al., Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab Dispos 2006; 34: 191-197.
66. Shitara Y, Hirano M, Sato H, Sugiyama Y,. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 2004; 311: 228-236.
67. Fujino H, Shimada S, Yamada I, Hirano M, Tsunenari Y, Kojima J,. Studies on the interaction between fibrates and statins using human hepatic microsomes. Arzneimittelforschung 2003; 53: 701-707.
68. Hinton LK, Galetin A, Houston JB,. Multiple inhibition mechanisms and prediction of drug-drug interactions: status of metabolism and transporter models as exemplified by gemfibrozil-drug interactions. Pharm Res 2008; 25: 1063-1074.
69. Honkalammi J, Niemi M, Neuvonen PJ, Backman JT,. Dose-dependent interaction between gemfibrozil and repaglinide in humans: strong inhibition of CYP2C8 with subtherapeutic gemfibrozil doses. Drug Metab Dispos 2011; 39: 1977-1986.
70. Honkalammi J, Niemi M, Neuvonen PJ, Backman JT,. Gemfibrozil is a strong inactivator of CYP2C8 in very small multiple doses. Clin Pharmacol Ther 2012; 91: 846-855.
71. Niemi M, Backman JT, Neuvonen M, Neuvonen PJ,. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia 2003; 46: 347-351.
72. Kudo T, Hisaka A, Sugiyama Y, Ito K,. Analysis of the repaglinide concentration increase produced by gemfibrozil and itraconazole based on the inhibition of the hepatic uptake transporter and metabolic enzymes. Drug Metab Dispos 2013; 41: 362-371.
73. Gertz M, Tsamandouras N, Sall C, Houston JB, Galetin A,. Reduced physiologically-based pharmacokinetic model of repaglinide: impact of OATP1B1 and CYP2C8 genotype and source of in vitro data on the prediction of drug-drug interaction risk. Pharm Res 2014; 31: 2367-2382.
74. Pang KS,. Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes (for the Gillette Review Series). Drug Metab Dispos 2003; 31: 1507-1519.
75. Kaminsky LS, Zhang Q-Y,. The small intestine as a xenobiotic-metabolizing organ. Drug Metab Dispos 2003; 31: 1520-1525.
76. Liu Y-T, Hao H-P, Xie H-G, et al., Extensive intestinal first-pass elimination and predominant hepatic distribution of berberine explain its low plasma levels in rats. Drug Metab Dispos 2010; 38: 1779-1784.
77. Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, Zeldin DC,. The human intestinal cytochrome P450 'pie'. Drug Metab Dispos 2006; 34: 880-886.
78. Von Richter O, Burk O, Fromm MF, Thon KP, Eichelbaum M, Kivistö KT,. Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther 2004; 75: 172-183.
79. Paine MF, Khalighi M, Fisher JM, et al., Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 1997; 283: 1552-1562.
80. Galetin A, Houston JB,. Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first-pass metabolism. J Pharmacol Exp Ther 2006; 318: 1220-1229.
81. Berggren S, Gall C, Wollnitz N, et al., Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine. Mol Pharm 2007; 4: 252-257.
82. Englund G, Rorsman F, Rönnblom A, et al., Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur J Pharm Sci 2006; 29: 269-277.
83. Li LY, Amidon GL, Kim JS, et al., Intestinal metabolism promotes regional differences in apical uptake of indinavir: coupled effect of P-glycoprotein and cytochrome P450 3A on indinavir membrane permeability in rat. J Pharmacol Exp Ther 2002; 301: 586-593.
84. Liu S, Tam D, Chen X, Pang KS,. P-glycoprotein and an unstirred water layer barring digoxin absorption in the vascularly perfused rat small intestine preparation: induction studies with pregnenolone-16α-carbonitrile. Drug Metab Dispos 2006; 34: 1468-1479.
85. Mouly S, Paine MF,. P-glycoprotein increases from proximal to distal regions of human small intestine. Pharm Res 2003; 20: 1595-1599.
86. Takara K, Ohnishi N, Horibe S, Yokoyama T,. Expression profiles of drug-metabolizing enzyme CYP3A and drug efflux transporter multidrug resistance 1 subfamily mRNAs in rat small intestine. Drug Metab Dispos 2003; 31: 1235-1239.
87. Bruyere A,. Declèves X, Bouzom F, et al. Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass. Mol Pharm 2010; 7: 1596-1607.
88. Badhan R, Penny J, Galetin A, Houston JB,. Methodology for development of a physiological model incorporating CYP3A and P-glycoprotein for the prediction of intestinal drug absorption. J Pharm Sci 2009; 98: 2180-2197.
89. Gertz M, Harrison A, Houston JB, Galetin A,. Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug Metab Dispos 2010; 38: 1147-1158.
90. Chow E, Sandy PK,. Why we need proper PBPK models to examine intestine and liver oral drug absorption. Curr Drug Metab 2013; 14: 57-79.
91. Sun H, Pang KS,. Physiological modeling to understand the impact of enzymes and transporters on drug and metabolite data and bioavailability estimates. Pharm Res 2010; 27: 1237-1254.
92. Lin JH, Chiba M, Baillie TA,. Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol Rev 1999; 51: 135-158.
93. Paine MF, Shen DD, Kunze KL, et al., First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 1996; 60: 14-24.
94. Fang C, Zhang Q-Y,. The role of small-intestinal P450 enzymes in protection against systemic exposure of orally administered benzo [a] pyrene. J Pharmacol Exp Ther 2010; 334: 156-163.
95. Zhang Q-Y, Kaminsky LS, Dunbar D, Zhang J, Ding X,. Role of small intestinal cytochromes P450 in the bioavailability of oral nifedipine. Drug Metab Dispos 2007; 35: 1617-1623.
96. Zhu Y, D'Agostino J, Zhang Q-Y,. Role of intestinal cytochrome P450 (P450) in modulating the bioavailability of oral lovastatin: insights from studies on the intestinal epithelium-specific P450 reductase knockout mouse. Drug Metab Dispos 2011; 39: 939-943.
97. van Herwaarden AE, Wagenaar E, van der Kruijssen CM, et al., Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J Clin Invest 2007; 117: 3583-3592.
98. Brooks RA, Gooderham NJ, Edwards RJ, Boobis AR, Winton DJ,. The mutagenicity of benzo [a] pyrene in mouse small intestine. Carcinogenesis 1999; 20: 109-114.
99. Quinney SK, Galinsky RE, Jiyamapa-Serna VA, et al., Hydroxyitraconazole, formed during intestinal first-pass metabolism of itraconazole, controls the time course of hepatic CYP3A inhibition and the bioavailability of itraconazole in rats. Drug Metab Dispos 2008; 36: 1097-1101.
100. Yan GZ, Generaux CN, Yoon M, et al., A semiphysiologically based pharmacokinetic modeling approach to predict the dose-exposure relationship of an antiparasitic prodrug/active metabolite pair. Drug Metab Dispos 2012; 40: 6-17.
101. Zhang Q-Y, Fang C, Zhang J, Dunbar D, Kaminsky L, Ding X,. An intestinal epithelium-specific cytochrome P450 (P450) reductase-knockout mouse model: direct evidence for a role of intestinal p450s in first-pass clearance of oral nifedipine. Drug Metab Dispos 2009; 37: 651-657.
102. Zhao P, Zhang L, Grillo JA, et al., Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharmacol Ther 2011; 89: 259-267.
103. Vieira ML, Zhao P, Berglund EG, et al., Predicting drug interaction potential with a physiologically based pharmacokinetic model: a case study of telithromycin, a time-dependent CYP3A inhibitor. Clin Pharmacol Ther 2012; 91: 700-708.
104. Pang KS, Morris ME, Sun H,. Formed and preformed metabolites: facts and comparisons. J Pharm Pharmacol 2008; 60: 1247-1275.
105. Fan J, Chen S, Chow EC, Pang KS,. PBPK modeling of intestinal and liver enzymes and transporters in drug absorption and sequential metabolism. Curr Drug Metab 2010; 11: 743-761.
106. Lown KS, Thummel KE, Benedict PE, et al., The erythromycin breath test predicts the clearance of midazolam. Clin Pharmacol Ther 1995; 57: 16-24.
107. Paine MF, Shen DD, Kunze KL, et al., First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 1996; 60: 14-24.
108. Thummel KE, O'Shea D, Paine MF, et al., Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 1996; 59: 491-502.
109. Doherty MM, Pang KS,. Route-dependent metabolism of morphine in the vascularly perfused rat small intestine preparation. Pharm Res 2000; 17: 291-298.
110. Greiner B, Eichelbaum M, Fritz P, et al., The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999; 104: 147-153.
111. Granger D, Richardson P, Kvietys P, Mortillaro N,. Intestinal blood flow. Gastroenterology 1980; 78: 837-863.
112. Cong D, Doherty M, Pang KS,. A new physiologically based, segregated-flow model to explain route-dependent intestinal metabolism. Drug Metab Dispos 2000; 28: 224-235.
113. Gertz M, Houston JB, Galetin A,. Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction. Drug Metab Dispos 2011; 39: 1633-1642.
114. Yang J, Jamei M, Yeo KR, Tucker GT, Rostami-Hodjegan A,. Prediction of intestinal first-pass drug metabolism. Curr Drug Metab 2007; 8: 676-684.
115. Roberts MS, Rowland M,. Hepatic elimination-dispersion model. J Pharm Sci 1985; 74: 585-587.
116. Sun H, Pang KS,. Physiological modeling to understand the impact of enzymes and transporters on drug and metabolite data and bioavailability estimates. Pharm Res 2010; 27: 1237-1254.
117. Gut model. Drug Metab Dispos 2012; 40: 1869-1877.
118. 3 up-regulates P-glycoprotein via the vitamin D receptor and not farnesoid X receptor in both fxr (-/-) and fxr (+/+) mice and increased renal and brain efflux of digoxin in mice in vivo. J Pharmacol Exp Ther 2011; 337: 846-859.
119. Hisaka A, Ohno Y, Yamamoto T, Suzuki H,. Theoretical considerations on quantitative prediction of drug-drug interactions. Drug Metab Pharmacokinet 2010; 25: 48-61.
120. Callegari E, Kalgutkar AS, Leung L, Obach RS, Plowchalk DR, Tse S,. Drug metabolites as cytochrome P450 inhibitors: a retrospective analysis and proposed algorithm for evaluation of the pharmacokinetic interaction potential of metabolites in drug discovery and development. Drug Metab Dispos 2013; 41: 2047-2055.
121. Yu H, Tweedie D,. A perspective on the contribution of metabolites to drug-drug interaction potential: the need to consider both circulating levels and inhibition potency. Drug Metab Dispos 2013; 41: 536-540.
122. Isoherranen N, Hachad H, Yeung CK, Levy RH,. Qualitative analysis of the role of metabolites in inhibitory drug-drug interactions: literature evaluation based on the metabolism and transport drug interaction database. Chem Res Toxicol 2009; 22: 294-298.
123. Yeung CK, Fujioka Y, Hachad H, Levy RH, Isoherranen N,. Are circulating metabolites important in drug-drug interactions?: quantitative analysis of risk prediction and inhibitory potency. Clin Pharmacol Ther 2011; 89: 105-113.
124. Isoherranen N, Kunze KL, Allen KE, Nelson WL, Thummel KE,. Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab Dispos 2004; 32: 1121-1131.
125. Templeton I, Thummel KE, Kharasch ED, et al., Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo. Clin Pharmacol Ther 2008; 83: 77-85.
126. Templeton I, Peng C, Thummel K, Davis C, Kunze K, Isoherranen N,. Accurate prediction of dose-dependent CYP3A4 inhibition by itraconazole and its metabolites from in vitro inhibition data. Clin Pharmacol Ther 2010; 88: 499-505.
127. VandenBrink BM, Isoherranen N,. The role of metabolites in predicting drug-drug interactions: focus on irreversible P450 inhibition. Curr Opin Drug Discov Devel 2010; 13: 66.
128. Bertelsen KM, Venkatakrishnan K, Von Moltke LL, Obach RS, Greenblatt DJ,. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab Dispos 2003; 31: 289-293.
129. Hanson KL, VandenBrink BM, Babu KN, Allen KE, Nelson WL, Kunze KL,. Sequential metabolism of secondary alkyl amines to metabolic-intermediate complexes: opposing roles for the secondary hydroxylamine and primary amine metabolites of desipramine,(s)-fluoxetine, and N-desmethyldiltiazem. Drug Metab Dispos 2010; 38: 963-972.
130. Zhang X, Jones DR, Hall SD,. Prediction of the effect of erythromycin, diltiazem, and their metabolites, alone and in combination, on CYP3A4 inhibition. Drug Metab Dispos 2009; 37: 150-160.
131. Shirasaka Y, Sager JE, Lutz JD, Davis C, Isoherranen N,. Inhibition of CYP2C19 and CYP3A4 by omeprazole metabolites and their contribution to drug-drug interactions. Drug Metab Dispos 2013; 41: 1414-1424.
132. Lutz JD, VandenBrink BM, Babu KN, Nelson WL, Kunze KL, Isoherranen N,. Stereoselective inhibition of CYP2C19 and CYP3A4 by fluoxetine and its metabolite: implications for risk assessment of multiple time-dependent inhibitor systems. Drug Metab Dispos 2013; 41: 2056-2065.
133. Tornio A, Filppula AM, Kailari O, et al., Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions. Clin Pharmacol Ther 2014; 96: 498-507.
134. Grillo JA, Zhao P, Bullock J, et al., Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice. Biopharm Drug Dispos 2012; 33: 99-110.
135. Moore KT, Vaidyanathan S, Natarajan J, Ariyawansa J, Haskell L, Turner KC,. An open-label study to estimate the effect of steady-state erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function. J Clin Pharmacol 2014; 54: 1407-1420.